January 2026 brought major GLP-1 updates, from the launch of the first oral Wegovy pill to a new federal insurance model that contrasts sharply with growing state-level restrictions. This roundup synthesizes the key clinical and regulatory news, providing practice-focused takeaways on what providers need to know about the evolving landscape.

The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.

The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.

October 2025 delivered major breakthroughs in GLP-1 therapy—from tirzepatide’s cardiovascular benefits to the rise of precision obesity medicine. Learn how these findings, along with AI-human coaching and oral GLP-1s, are redefining evidence-based weight management.

September 2025 brought several notable developments in the GLP-1 and weight management space, including new clinical trial data, regulatory guidance changes, and policy updates from the WHO. This monthly update summarizes what clinicians need to know about oral formulations, higher-dose therapies, muscle preservation strategies, and expanding therapeutic applications.

August 2025 delivered critical clinical practice updates for GLP-1 therapy, including the first generic weight loss approval (Teva’s Saxenda), FDA expansion of Wegovy for liver disease treatment, and major oral formulation breakthroughs from Eli Lilly and Viking Therapeutics. These evidence-based developments provide healthcare providers with new treatment options, expanded patient populations, and enhanced safety protocols that directly impact clinical decision-making.

For GLP‑1 weight loss providers, the latest research, reimbursement changes, and pipeline drugs are redefining how you support patients. This roundup offers concise guidance on preserving lean mass, improving adherence, navigating coverage, and preparing for next‑generation therapies.

GLP-1 trends in June 2025 are redefining obesity treatment—but real-world data reveals more than half of patients quit within a year. This article explores why, what’s coming next, and how providers can adapt to a rapidly changing landscape.

Botox patient satisfaction now defines success in modern aesthetic practice. This guide shows new injectors how to capture feedback, build trust, and grow their business.

Semaglutide is effective for weight loss—but nearly 35% of that loss can be lean muscle. The COURAGE trial from Regeneron explores a novel antibody co-therapy that may protect muscle and improve fat loss outcomes, setting a new bar for obesity treatment.